Instil Bio (TIL) Stock Price, News & Analysis

Company Overview

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for the treatment of solid tumors. The company’s research centers on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded or modified in the laboratory, and returned to the patient to help recognize and attack cancer cells.

Instil Bio is advancing engineered TIL candidates designed to improve the activity, persistence, and scalability of cell therapy. Its development programs are intended to address cancers that have historically been difficult to treat with existing immunotherapies, including multiple advanced solid tumors. The company’s pipeline and clinical programs remain focused on evaluating the safety and potential effectiveness of these investigational therapies.

Instil Bio is headquartered in the United States and conducts its research and development activities through clinical and biotechnology operations supporting its TIL platform. As with other clinical-stage biotechnology companies, its products are investigational and require successful clinical testing and regulatory review before they can be commercially available.

Key Stats

• Today's Range: $5.91 to $6.45
• 50-Day Range: $5.91 to $7.86
• 52-Week Range: $5.67 to $20.33
• Volume: 25,172 shs
• Average Volume: 23,034 shs
• Market Capitalization: $40.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Reduce

Instil Bio Stock Analysis - MarketRank™

Instil Bio scored higher than 40% of companies evaluated by MarketBeat, and ranked 697th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Reduce

Consensus Rating

Instil Bio has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Instil Bio has a consensus price target of $7.00, representing about 18.4% upside from its current price of $5.91.

Amount of Analyst Coverage

Instil Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Instil Bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.43% of the float of Instil Bio has been sold short.

Short Interest Ratio / Days to Cover

Instil Bio has a short interest ratio ("days to cover") of 9.31.

Change versus previous month

Short interest in Instil Bio has recently decreased by 1.75%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Instil Bio does not currently pay a dividend.

Dividend Growth

Instil Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Instil Bio has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Instil Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

47.00% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TIL
• CIK: 1625584
• Web: www.tillcap.com
• Phone: 972-499-3350
• Fax: N/A
• Employees: 410
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Instil Bio: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +18.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.37 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.78%
• Return on Assets: -14.89%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 21.67
• Quick Ratio: 21.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.79 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 6,780,000
• Free Float: 3,594,000
• Market Cap: $40.07 million
• Optionable: No Data
• Beta: 1.94